Monika Richter focuses her practice on the biotechnology and pharmaceuticals sector. She advises national and international clients on various legal matters related to the development and partnering of pharmaceutical compounds and products, with a particular focus on strategic alliances, license agreements, research collaborations and co-development agreements. Her work likewise includes financing and corporate transactions as well as mergers and acquisitions.

Lire la suite


  • Advised Paion, a German biotechnology company, on a licensing transaction with a global pharmaceutical company regarding local rights in its asset Remimazolam*
  • Advised Selvita, one of Poland’s largest biotechnology companies, on various international licensing and collaboration agreements, including with Orion Pharma, H3, Felicitex, Merck KGaA, Menarini and on a funding agreement with the Leukemia and Lymphoma Society*
  • Advised a big Polish pharmaceutical company on a research collaboration with a German pharmaceutical company*

Lire la suite


  • Handelsblatt/Best Lawyers™ 2022 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
  • Leaders League’s 2019 guide, Innovation, Technology & Patents, “Excellent” in the Health, pharma & biotechnology category
  • The Legal 500 EMEA 2019


Humboldt University of Berlin, Dr. jur. (PhD), 2008
Court of Appeal, Berlin, Second State Exam, 2004
Universities of Tübingen and Heidelberg, First State Exam, 2002


Lire la suite

Dr. Monika Emilia Richter

Publications et événements / Médias

Webinar / McDermott Event / October 7, 2021